Comparison

DxScript vs Veradigm™ ePrescribe

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

DxScript

This ePrescribing service provides instant access to patient eligibility, benefits, and formulary information at the point of care. It helps prescribers choose covered medications, identify lower-cost alternatives, and view prescription history to reduce errors. The service streamlines prescription renewals, saving time and reducing manual processes.

Highlights
  • Real-time eligibility and benefits checks
  • Formulary information at point of care
  • Identification of lower-cost alternatives
  • Patient prescription history view
  • Electronic prescription writing
  • Streamlined prescription renewals
Read full description

DxScript® ePrescribing service puts eligibility, benefits, and formulary information at your fingertips at the time of prescribing. This enable prescriber to select medications that are on formulary and are covered by the patient's drug benefit. It also informs you of lower cost alternatives such as generic drugs. Prescriber can access a timely and clinically sound view of a patient's prescription history across providers, at the point of care. This decreases the risk of preventable medication errors. DxScript® replaces old, error-phone approach to writing. Printing new prescription electronically in your office reduces the risk of medication errors associated with poor handwriting, illegible faxes and manual data entry. Using DxScript® to process prescription renewals saves you time and money by dramatically reducing the number  of phone calls and faxes typically associated with the prescription renewal authorization process.

About

Veradigm™ ePrescribe

This medical app allows healthcare providers to electronically create and send prescriptions to pharmacies. It offers anytime, anywhere access to patient records and medication information, streamlining the prescription process with intuitive workflows.

Highlights
  • Transmit prescriptions electronically
  • Access patient records anytime
  • View current medications
  • Interaction alerts
  • Create new prescriptions quickly
  • Search for medications
  • Select pharmacies
Read full description

Veradigm ePrescribe Mobile enables providers to write and electronically transmit prescriptions to pharmacies. This version of the app is free for current ePrescribe Deluxe desktop users. • Access Anytime Anywhere: Helping you take care of your patients, increasing the quality of outcomes through timely decisions • Intuitive High Impact Workflows: a single workflow across desktop and mobile devices, providing the ability to quickly access patient records and review current medications effectively and efficiently Allscripts ePrescribe Mobile features include: • Select a location • Patient List / Schedule / Search • Patient Summary • Interaction alerts • Create a New Prescription in seconds • Medication Search • Details • Select SIG • Select Pharmacy • Alternatives for non-formulary meds

Screenshots

DxScript1 screens
Veradigm™ ePrescribe1 screens

Verdict

The call

The clearest difference is review sentiment: DxScript at 75% against Veradigm™ ePrescribe's 0%. DxScript also leads on rating (4.2 vs 1.6). Veradigm™ ePrescribe's advantage is ratings volume (29 vs 5) and iOS requirement (7.0 vs 14.5). On price, update cadence, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

DxScript holds the better App Store score, 4.2 against 1.6. That said, the two scores are not equally well evidenced: Veradigm™ ePrescribe has 29 ratings behind it against 5, so its average is the more settled of the two. Written reviews point the same way: 75% of DxScript's written reviews are positive against 0% of Veradigm™ ePrescribe's.

UpkeepUpdate frequency

DxScript ships an update every 7 months, Veradigm™ ePrescribe every 6 months. The most recent releases landed on July 4, 2026 and September 17, 2026 respectively.

Scorecard4 real differences · 6 level
DxScript versus Veradigm™ ePrescribe: the parameters behind the verdict, then further details
ParameterDxScriptVeradigm™ ePrescribe
PriceFreeFree
Rating4.2 (5 ratings) — better1.6 (29 ratings)
Positive reviews75.0% of reviews — better0.0% of reviews
Number of ratings529 — better
Update frequencyEvery 7 monthsEvery 6 months — better
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS14.57.0 — better
Further details — not scored
Size6 MB82 MB
Age rating17+17+
DeveloperNextGen Management LLCAllscripts Healthcare Solutions Inc

Customer experience

DxScript

All ratings5 ratings
Positive80.0%
Neutral0.0%
Negative20.0%
Written reviews4 reviews
Positive75.0%
Neutral0.0%
Negative25.0%

Veradigm™ ePrescribe

All ratings29 ratings
Positive13.8%
Neutral3.4%
Negative82.8%
Written reviews19 reviews
Positive0.0%
Neutral5.3%
Negative94.7%

In-app purchases

None

DxScript

No in-app purchases

None

Veradigm™ ePrescribe

No in-app purchases

Questions

Is DxScript free?
DxScript is free to download, with no in-app purchases.
Is Veradigm™ ePrescribe free?
Veradigm™ ePrescribe is free to download, with no in-app purchases.
Which has better reviews, DxScript or Veradigm™ ePrescribe?
DxScript is rated higher. DxScript averages 4.2 out of 5 from 5 ratings, while Veradigm™ ePrescribe averages 1.6 from 29 ratings.
Do DxScript or Veradigm™ ePrescribe have ads?
Neither DxScript nor Veradigm™ ePrescribe shows ads.
Which is updated more often, DxScript or Veradigm™ ePrescribe?
DxScript ships an update every 7 months, and Veradigm™ ePrescribe every 6 months. Most recently, DxScript was updated on July 4, 2026 and Veradigm™ ePrescribe on September 17, 2026.

Other comparisons